Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Triamcinolone (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms TYBEE
- Sponsors Clearside Biomedical
- 08 Nov 2017 According to a Clearside Biomedical media release, the company expects to announce preliminary data in the second quarter of 2018.
- 25 Oct 2017 Planned End Date changed from 1 Jul 2018 to 1 Apr 2018.
- 25 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.